MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 05-16-2026
Zynerba Pharmaceuticals General and Administrative Expenses 2011-2026 | ZYNE
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 M | 15.3 M | 16.4 M | 13.9 M | 13.2 M | 10 M | 6.43 M | 5.36 M | 4.08 M | 444 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.4 M | 444 K | 9.94 M |
Quarterly General and Administrative Expenses Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.97 M | 3.39 M | - | 3.45 M | 3.72 M | 3.76 M | - | 3.87 M | 4.39 M | 3.28 M | 4.57 M | 3.43 M | 4.49 M | 3.92 M | 3.96 M | 3.53 M | 3.29 M | 3.16 M | 3.26 M | 3.13 M | 3.44 M | 3.42 M | 2.38 M | 2.8 M | 2.63 M | 2.21 M | 1.78 M | 1.49 M | 1.48 M | 1.68 M | 2.16 M | 1.92 M | 631 K | 654 K | 663 K | 2.11 M | 1.21 M | 99.7 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.57 M | 99.7 K | 2.76 M |
General and Administrative Expenses of other stocks in the Drug manufacturers industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
11.9 M | $ 6.09 | 3.71 % | $ 90.5 M |  USA |
 |
Endo International plc
ENDP
|
568 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
15.1 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
32.9 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
390 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
7.48 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
10.5 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
13.2 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
138 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
10.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
18.5 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
42 M | $ 2.74 | 0.04 % | $ 1.05 B | Canada |
 |
Athenex
ATNX
|
44.9 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
153 M | $ 33.77 | 2.32 % | $ 1.24 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
181 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
935 M | - | - | $ 11.5 B | USA |
 |
Pacira BioSciences
PCRX
|
294 M | $ 24.21 | 3.68 % | $ 1.12 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
107 M | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
3.44 B | $ 5.37 | -1.83 % | $ 1.99 B | Canada |
 |
Organogenesis Holdings
ORGO
|
326 M | $ 2.66 | - | $ 337 M | USA |
 |
Canopy Growth Corporation
CGC
|
170 M | $ 1.05 | 0.48 % | $ 113 M | Canada |
 |
Solid Biosciences
SLDB
|
38.9 M | $ 6.83 | 3.17 % | $ 598 M | USA |
 |
Aurora Cannabis
ACB
|
97.3 M | $ 3.45 | -0.29 % | $ 189 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
7.36 M | $ 1.07 | -2.73 % | $ 1.33 M | USA |
 |
Tilray
TLRY
|
165 M | $ 5.42 | 2.36 % | $ 3.35 B | Canada |
 |
Jupiter Wellness
JUPW
|
35.7 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
81 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
19.1 M | $ 1.13 | 0.45 % | $ 108 M | Canada |
 |
Evolus
EOLS
|
221 M | $ 6.23 | 2.22 % | $ 402 M | USA |
 |
Sundial Growers
SNDL
|
38.4 M | $ 1.44 | -0.68 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
186 M | $ 9.09 | 7.57 % | $ 486 M | USA |
 |
Veru
VERU
|
19.9 M | $ 2.31 | -1.7 % | $ 33.8 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
28.3 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
69 M | $ 23.44 | - | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
34.4 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
131 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
196 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
32.2 M | $ 7.02 | -0.28 % | $ 277 M | USA |
 |
Recro Pharma
REPH
|
21 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
79.8 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
14.4 M | $ 0.71 | -2.56 % | $ 35.5 M | USA |
 |
PLx Pharma
PLXP
|
40 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
3.79 B | $ 16.35 | -1.77 % | $ 19 B | USA |
 |
Zomedica Corp.
ZOM
|
24.5 M | - | -0.21 % | $ 98 M | USA |
 |
Rockwell Medical
RMTI
|
14 M | $ 0.77 | -3.34 % | $ 27.7 M | USA |
 |
Tricida
TCDA
|
37.6 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
2.45 M | $ 0.76 | 0.07 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
6.85 M | $ 2.11 | -0.47 % | $ 24.4 M | USA |